Patents by Inventor Steven Braithwaite

Steven Braithwaite has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING DYSKINESIA
    Publication number: 20220257590
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action ?-opioid receptor antagonist/?-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a ?-opioid receptor antagonist or prodrug thereof, and a ?-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Application
    Filed: April 29, 2022
    Publication date: August 18, 2022
    Inventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • METHODS FOR SCREENING HUMAN BLOOD PRODUCTS COMPRISING PLASMA USING IMMUNOCOMPROMISED RODENT MODELS
    Publication number: 20210236656
    Abstract: Methods and compositions are provided for screening candidate compositions for activity with respect to treatment of aging-associated conditions, e.g., cognitive impairment conditions or age-related dementia. Aspects of the methods include administering a human blood product comprising plasma, to an immunocompromised animal, e.g., a mouse or a rat, and measuring the effect of the product on an endpoint, e.g., neurogenesis, locomotor activity, anxiety, spatial memory, and hippocampus-dependent memory.
    Type: Application
    Filed: January 20, 2021
    Publication date: August 5, 2021
    Inventors: Steven Braithwaite, Saul A. Villeda, Anton Wyss-Coray
  • Methods for screening human blood products comprising plasma using immunocompromised rodent models
    Patent number: 10905779
    Abstract: Methods and compositions are provided for screening candidate compositions for activity with respect to treatment of aging-associated conditions, e.g., cognitive impairment conditions or age-related dementia. Aspects of the methods include administering a human blood product comprising plasma, to an immunocompromised animal, e.g., a mouse or a rat, and measuring the effect of the product on an endpoint, e.g., neurogenesis, locomotor activity, anxiety, spatial memory, and hippocampus-dependent memory.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: February 2, 2021
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, ALKAHEST, INC.
    Inventors: Steven Braithwaite, Saul A. Villeda, Anton Wyss-Coray
  • Method of treating dyskinesia
    Patent number: 10736889
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action ?-opioid receptor antagonist/?-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a ?-opioid receptor antagonist or prodrug thereof, and a ?-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: August 11, 2020
    Assignee: Rutgers, The State University of New Jersey
    Inventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Method of Treating Dyskinesia
    Publication number: 20180185355
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action ?-opioid receptor antagonist/-?-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a ?-opioid receptor antagonist or prodrug thereof, and a ?-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Application
    Filed: March 1, 2018
    Publication date: July 5, 2018
    Inventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Method of treating dyskinesia
    Patent number: 9918980
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action ?-opioid receptor antagonist/?-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: March 20, 2018
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • METHODS FOR SCREENING HUMAN BLOOD PRODUCTS COMPRISING PLASMA USING IMMUNOCOMPROMISED RODENT MODELS
    Publication number: 20170232118
    Abstract: Methods and compositions are provided for screening candidate compositions for activity with respect to treatment of aging-associated conditions, e.g., cognitive impairment conditions or age-related dementia. Aspects of the methods include administering a human blood product comprising plasma, to an immunocompromised animal, e.g., a mouse or a rat, and measuring the effect of the product on an endpoint, e.g., neurogenesis, locomotor activity, anxiety, spatial memory, and hippocampus-dependent memory.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 17, 2017
    Inventors: Steven Braithwaite, Saul A. Villeda, Anton Wyss-Coray
  • Method of Treating Dyskinesia
    Publication number: 20160151359
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action ?-opioid receptor antagonist/?-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Application
    Filed: February 9, 2016
    Publication date: June 2, 2016
    Inventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Method of treating dyskinesia
    Patent number: 9289423
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action mu-opioid receptor antagonist/kappa-opioid receptor agonist or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: March 22, 2016
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Mary Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Compositions and Methods of Reducing Sedation
    Publication number: 20150352099
    Abstract: Methods and compositions useful in reducing drug-induced sedation in subjects.
    Type: Application
    Filed: June 4, 2015
    Publication date: December 10, 2015
    Applicants: Mentinova Inc., Rutgers, The State University of New Jersey
    Inventors: Steven Braithwaite, Michael Voronkov, M. Maral Mouradian
  • Method of Treating Dyskinesia
    Publication number: 20140221415
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action mu-opioid receptor antagonist/kappa-opioid receptor agonist or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Application
    Filed: April 26, 2012
    Publication date: August 7, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Interaction of NMDA receptor with the protein tyrosine phosphatase step in psychotic disorders
    Publication number: 20050221411
    Abstract: The present invention relates to the identification of STEP being as involved in signaling pathways relating to psychotic diseases, including schizophrenia, and other disorders in which NMDA receptor dysfunction is implicated. The present invention provides methods for screening STEP inhibitors that modulate NMDA-R signaling. The present invention also provides methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling.
    Type: Application
    Filed: April 15, 2005
    Publication date: October 6, 2005
    Inventors: Steven Braithwaite, Jasna Jerecic, Roman Urfer
  • Interaction of NMDA receptor with the protein tyrosine phosphatase step in psychotic disorders
    Publication number: 20050142630
    Abstract: The present invention relates to the identification of STEP being as involved in signaling pathways relating to psychotic diseases, including schizophrenia, and other disorders in which NMDA receptor dysfunction is implicated. The present invention provides methods for screening STEP inhibitors that modulate NMDA-R signaling. The present invention also provides methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling.
    Type: Application
    Filed: December 8, 2004
    Publication date: June 30, 2005
    Inventors: Steven Braithwaite, Jasna Jerecic, Roman Urfer
  • Interaction of NMDA receptor with protein tyrosine phosphatase
    Publication number: 20030092071
    Abstract: The present invention relates to the identification of a binding between NMDA receptor (NMDA-R) subunits and a protein tyrosine phosphatase (PTP), e.g., PTPL1. The present invention provides methods for screening a PTP agonist or antagonist that modulates NMDA-R signaling. The present invention also provides methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling. The present invention further provides methods for isolating PTPL1 from a biological preparation.
    Type: Application
    Filed: September 18, 2002
    Publication date: May 15, 2003
    Inventors: Jasna Jerecic, Steven Braithwaite, Kalev Kask, Jenkuei Liu, Thorsten Melcher